Tags

Type your tag names separated by a space and hit enter

[Update - Lithium in the Long-Term Treatment of Bipolar Disorders].
Fortschr Neurol Psychiatr. 2018 Dec; 86(12):745-753.FN

Abstract

Lithium is the gold standard in the long-term treatment of bipolar disorders and the only substance with a convincing antisuicidal effect in affective disorders. Under regular monitoring, lithium represents mostly a well-tolerated and safe medication. Balancing risk and benefits shows that lithium can also be an off-label therapeutic option during pregnancy and breast feeding. Lithium may exhibit neuroprotective effects and has been linked to a reduced risk of Alzheimer's disease and stroke. In the future, biomarkers of lithium response may be available that enable development of more personalized therapies.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Petzold J
Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Psychiatrie und Psychotherapie.
Bauer M
Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Psychiatrie und Psychotherapie.
Severus E
Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Psychiatrie und Psychotherapie.

MeSH

Alzheimer DiseaseBipolar DisorderHumansLithium CompoundsMood DisordersNeuroprotective AgentsTime Factors

Pub Type(s)

Journal Article
Review

Language

ger

PubMed ID

30419584

Citation

Petzold, Johannes, et al. "[Update - Lithium in the Long-Term Treatment of Bipolar Disorders]." Fortschritte Der Neurologie-Psychiatrie, vol. 86, no. 12, 2018, pp. 745-753.
Petzold J, Bauer M, Severus E. [Update - Lithium in the Long-Term Treatment of Bipolar Disorders]. Fortschr Neurol Psychiatr. 2018;86(12):745-753.
Petzold, J., Bauer, M., & Severus, E. (2018). [Update - Lithium in the Long-Term Treatment of Bipolar Disorders]. Fortschritte Der Neurologie-Psychiatrie, 86(12), 745-753. https://doi.org/10.1055/a-0633-2511
Petzold J, Bauer M, Severus E. [Update - Lithium in the Long-Term Treatment of Bipolar Disorders]. Fortschr Neurol Psychiatr. 2018;86(12):745-753. PubMed PMID: 30419584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Update - Lithium in the Long-Term Treatment of Bipolar Disorders]. AU - Petzold,Johannes, AU - Bauer,Michael, AU - Severus,Emanuel, Y1 - 2018/11/12/ PY - 2018/11/13/pubmed PY - 2019/7/28/medline PY - 2018/11/13/entrez SP - 745 EP - 753 JF - Fortschritte der Neurologie-Psychiatrie JO - Fortschr Neurol Psychiatr VL - 86 IS - 12 N2 - Lithium is the gold standard in the long-term treatment of bipolar disorders and the only substance with a convincing antisuicidal effect in affective disorders. Under regular monitoring, lithium represents mostly a well-tolerated and safe medication. Balancing risk and benefits shows that lithium can also be an off-label therapeutic option during pregnancy and breast feeding. Lithium may exhibit neuroprotective effects and has been linked to a reduced risk of Alzheimer's disease and stroke. In the future, biomarkers of lithium response may be available that enable development of more personalized therapies. SN - 1439-3522 UR - https://www.unboundmedicine.com/medline/citation/30419584/[Update___Lithium_in_the_Long_Term_Treatment_of_Bipolar_Disorders]_ DB - PRIME DP - Unbound Medicine ER -